Tehran University of Medical Sciences Iranian Journal of Allergy, Asthma and Immunology 1735-1502 19 S1 2020 05 17 3 6 Abdol Majid Cheraghali Faculty of Pharmacy, Baqiyatallah University of Medical Sciences, Tehran, Iran Hassan Abolghasemi Faculty of Medicine, Baqiyatallah University of Medical Sciences, Tehran, Iran Peyman Eshghi Faculty of Medicine, Shahid Beheshti University of Medical Sciences and Iran Blood Transfusion Organization; Tehran, Iran 2020 04 19 2020 04 27 Abstract Abstract Abstract Abstract Abstract https://ijaai.tums.ac.ir/index.php/ijaai/article/view/2799

Tehran University of Medical Sciences Iranian Journal of Allergy, Asthma and Immunology 1735-1502 19 S1 2020 05 17 1 2 Maryam Nourizadeh Immunology, Asthma and Allergy Research Institute, Tehran University of Medical Sciences, Tehran, Iran Mohammad Javad Rasaee Department of Clinical Biochemistry, School of Medical Sciences, Tarbiat Modares University (TMU), Tehran, Iran Mostafa Moin Immunology, Asthma and Allergy Research Institute, Tehran University of Medical Sciences, Tehran, Iran 2020 05 06 2020 05 08 Abstract Abstract Abstract Abstract https://ijaai.tums.ac.ir/index.php/ijaai/article/view/2817

Tehran University of Medical Sciences Iranian Journal of Allergy, Asthma and Immunology 1735-1502 19 S1 2020 05 17 7 9 Ali Esmaeili Vardanjani Department of Critical Care Nursing and Management, School of Nursing and Midwifery, Tehran University of Medical Sciences, Tehran, Iran AND Department of Nursing, Faculty Member, Hamadan University of Medical Sciences, Hamadan, Iran Siamak Moayedi Department of Emergency Medicine, University of Maryland School of Medicine, Baltimore, U.S.A Mohammad Golitaleb Department of Critical Care Nursing, School of Nursing, Arak University of Medical Sciences, Arak, Iran 2020 03 27 2020 04 24 Abstract Abstract Abstract Abstract https://ijaai.tums.ac.ir/index.php/ijaai/article/view/2760

Tehran University of Medical Sciences Iranian Journal of Allergy, Asthma and Immunology 1735-1502 19 S1 2020 05 17 10 12 EN Farzaneh Dastan Department of Clinical Pharmacy, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran AND Chronic Respiratory Diseases Research Center, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran Atefeh Abedini Chronic Respiratory Diseases Research Center, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran Shahram Shahabi Department of Research and Development, SHC-Hyland's Inc., Los Angeles, California, U.S.A Arda Kiani Chronic Respiratory Diseases Research Center, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran Ali Saffaei Student Research Committee, Department of Clinical Pharmacy, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran Ahad Zare Sarem Cell Research Center (SCRC), Sarem Women's Hospital, Tehran, Iran AND Department of Immunology, Faculty of Medicine, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran 2020 04 26 2020 05 11 Abstract Abstract Abstract Abstract   https://ijaai.tums.ac.ir/index.php/ijaai/article/view/2805

Tehran University of Medical Sciences Iranian Journal of Allergy, Asthma and Immunology 1735-1502 19 S1 2020 05 17 13 17 Seyed-Mohammad Ghahestani Children’s Medical Center Hospital, Tehran University of Medical Sciences, Tehran, Iran Javad Mahmoudi Neurosciences Research Center, Tabriz University of Medical Sciences, Tabriz, Iran Sakineh Hajebrahimi Research Center for Evidence-Based-Medicine, Iranian EBM Center, A JBI Affiliated Center of Excellence, Tabriz University of Medical Sciences, Tabriz, Iran AND Department of Urology, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran Amir-Babak Sioofy-Khojine Research Center for Evidence-Based-Medicine, Iranian EBM Center, A JBI Affiliated Center of Excellence, Tabriz University of Medical Sciences, Tabriz, Iran AND Faculty of Medicine and Life Technologies, Tampere University, Tampere, Finland AND Research Center for Infectious and Tropical Disease, Tabriz University of Medical Sciences, Tabriz, Iran Hanieh Salehi-Pourmehr Research Center for Evidence-Based-Medicine, Iranian EBM Center, A JBI Affiliated Center of Excellence, Tabriz University of Medical Sciences, Tabriz, Iran Fatemeh Sadeghi-Ghyassi Research Center for Evidence-Based-Medicine, Iranian EBM Center, A JBI Affiliated Center of Excellence, Tabriz University of Medical Sciences, Tabriz, Iranersity of Medical Sciences, Tabriz, Iran 7 Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria Hadi Mostafaei Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria 2020 04 11 2020 04 22 The new virus SARS-CoV-2 is savagely spreading out over the world. The biologic studies show that the target receptor for the virus might be angiotensin-converting enzyme 2 (ACE2). This peptide is responsible for converting angiotensin II (Ang II), which is a profoundly active peptide, into Ang 1-7 with quite a balancing barbell function. It is emphasized that the direct target of the virus is ACE2 underlining the obvious difference with ACE. Nevertheless, we hypothesized that a back load build up effect on Ang II may usurp the ACE capacity and subsequently leave the bradykinin system unabated. We think there are clinical clues for dry cough and the presumed aggravating role of ACE inhibitors like captopril on the disease process. Thereby, we speculated that inhibition of bradykinin synthesis and/or blockade of bradykinin B2 receptor using Aprotinin/ecallantide and Icatibant, respectively, may hold therapeutic promise in severe cases and these molecules can be advanced to clinical trials. https://ijaai.tums.ac.ir/index.php/ijaai/article/view/2785

Tehran University of Medical Sciences Iranian Journal of Allergy, Asthma and Immunology 1735-1502 19 S1 2020 05 17 18 26 EN Reza Jafari Solid Tumor Research Center, Cellular and Molecular Medicine Institute, Urmia University of Medical Sciences, Urmia, Iran AND Department of Immunology and Genetics, School of Medicine, Urmia University of Medical Sciences, Urmia, Iran Mostafa Moin Immunology, Asthma, and Allergy Research Institute, Children’s Medical Center Hospital, Tehran University of Medical Sciences, Tehran, Iran Fatah Kashanchi School of Systems Biology, Laboratory of Molecular Virology, George Mason University, Manassas, VA, U.S.A Alireza Ranjbar School of Systems Biology, Laboratory of Molecular Virology, George Mason University, Manassas, VA, USA 5 Institute of Interventional Allergology and Immunology, Bonn/Cologne, Bonn, Germany AND International Prof. Dr. Alireza Yalda Foundation in Medical Sciences, Bonn/Cologne, Bonn, Germany 2020 01 24 2020 03 30 In light of various supports of prodigious figures in the field of immunology and allergy, the subject area has been faced a great leap during the last century. The current state of the discipline owes an abundant appreciation for the scholars motivated in escalating the true nature of the science, who left no stone unturned in improving the general common sense and understanding of the human knowledge in general, and immunology and allergy in particular. Professor Reza Farid Hosseini is among the dignitaries who invested his life and energy on weaving the tapestry of the immunology and allergy. He delivered a great deal of influence on the field by his ethical devotion to science and was a significant contributor in the realms of the human immune system. His presence drastically rehabilitated the place of the Immunology in Iran, and the current paper seeks to review the personal and academic life of Professor Reza Farid Hosseini in honor and appreciation for his in-depth involvement in the field. The paper summarizes Professor Farid’s childhood, school, and higher education, compilations, and translation of books, his contribution to the research both inside and outside of Iran, and scientific activities of Dr. Farid Hosseini. https://ijaai.tums.ac.ir/index.php/ijaai/article/view/2691

Tehran University of Medical Sciences Iranian Journal of Allergy, Asthma and Immunology 1735-1502 19 S1 2020 05 17 27 42 Javad Poursamimi Allergy Research Center, Mashhad University of Medical Sciences, Mashhad, Iran AND Student Research Committee, Mashhad University of Medical Sciences, Mashhad, Iran Zhaleh Shariati-Sarabi Rheumatic Diseases Research Center, Mashhad University of Medical Sciences, Mashhad, Iran AND Department of Internal Medicine, Imam Reza Hospital, Mashhad University of Medical Sciences, Mashhad, Iran Jalil Tavakkol-Afshari Immunology Research Center, Mashhad University of Medical Sciences, Mashhad, Iran Seyed Ahmad Mohajeri Pharmaceutical Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran Mojgan Mohammadi Immunology Research Center, Mashhad University of Medical Sciences, Mashhad, Iran AND Department of Immunology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran 2019 11 05 2019 12 06 It has been reported that patients with arthritis, osteoarthritis, atherosclerosis, coronary artery disease, brain ischemia, diabetes, and inflammatory bowel disease (IBD) suffer from pro-inflammatory and oxidant related responses. Therefore, anti-inflammatory and anti-oxidant therapies are used to improve the quality of life of the patients. Saffron is a herbal drug that has immunomodulatory and antioxidant properties. Hence, Saffron and its components have been proposed as therapeutic agents for the treatment of the diseases. Therefore, this review article was designed to collect recent information regarding the effects of saffron and its components on the amelioration of the inflammatory symptoms in the autoimmune and non-autoimmune diseases and anti-cancerous effects from 1999 up to now via searching the Pubmed, Google Scholar, and Scopus databases. Due to fact that several investigations have reviewed the roles played by Saffron on autoimmune and non-autoimmune diseases such as multiple sclerosis, mood disorders, and Alzheimer's disease, this review article focuses on other diseases to keep the novelty of the present review for readers. https://ijaai.tums.ac.ir/index.php/ijaai/article/view/2586

Tehran University of Medical Sciences Iranian Journal of Allergy, Asthma and Immunology 1735-1502 19 S1 2020 05 17 43 54 EN Peyman Bemani Department of Immunology, Shiraz Medical School, Shiraz University of Medical Sciences, Shiraz, Iran AND Student Research Committee, Shiraz University of Medical Sciences, Shiraz, Iran Zahra Amirghofran Department of Immunology, Shiraz Medical School, Shiraz University of Medical Sciences, Shiraz, Iran AND Autoimmune Diseases Research Center, Shiraz University of Medical Sciences, Shiraz, Iran Eskandar Kamali-Sarvestani Department of Immunology, Shiraz Medical School, Shiraz University of Medical Sciences, Shiraz, Iran AND Autoimmune Diseases Research Center, Shiraz University of Medical Sciences, Shiraz, Iran 2019 10 04 2019 12 03 Though the exact etiology of rheumatoid arthritis (RA) is unknown, the contribution of immune cells in the disease process is completely acknowledged. T helper (Th) 1 and Th17-related cytokines are required for the disease development and progression, while Th2 and regulatory T cells (Tregs)-derived cytokines are protective. Studies have shown that sodium benzoate (NaB) can switch the balance of Th cell subsets toward Th2 and Tregs. The present study aimed to evaluate the possible effects of NaB on the expression of CD4+T cells-related cytokines and transcription factors in splenocytes derived from an animal model of RA, adjuvant-induced arthritis (AIA). AIA was induced in rats by injection of Freund's adjuvant containing mycobacterial antigens (Mtb). Splenocytes were isolated from AIA rats and restimulated ex vivo with Mtb in the presence or absence of NaB for 24 h. To determine the effects of NaB on the expression of T cells-related cytokine and transcription factor genes, real-time PCR was performed. NaB treatment of Mtb-stimulated splenocytes derived from arthritic rats resulted in significant increases in the gene expressions of Tregs-related cytokines (IL-10 and TGF-β) and Foxp3 transcription factor, and significant decreases in the expression of Th1-related cytokines (TNF-α and IFN-γ) and the T-bet transcription factor. The ratios of Th1/Th2 (IFN-γ/IL-4), Th1/Treg (IFN-γ/TGF-β and IFN-γ/IL-10) and Th17/Treg (IL-17/IL-10 and IL-17/IL-10+TGF-β)-related cytokines were ROR-γt and those of the cytokines IL-4, IL-5, IL-13, and IL-17, representing both T helper (Th)2 and Th17 responses, were lower in the IL-37 group in comparison with the Der f group. However, the Th1 responsewas not suppressed after administration of IL-37. IL-37 increased the IL-10 level; however, Real-Time PCR, western blotting, and flow cytometry results showed the limited action of IL-37 on CD4+CD25+Foxp3+T cells. This study demonstrates that intranasal IL-37 can suppress Th2 and Th17 responses in an AR murine model. Furthermore, these data suggest that IL-10 is increased, but CD4+CD25+Foxp3+T cells are not correlated with the IL-37-induced mechanism.   https://ijaai.tums.ac.ir/index.php/ijaai/article/view/1104 https://ijaai.tums.ac.ir/index.php/ijaai/article/download/1104/762

Tehran University of Medical Sciences Iranian Journal of Allergy, Asthma and Immunology 1735-1502 16 5 2017 10 28 418 424 EN Mohammad Taghi Palizgir Rheumatology Research Center, Tehran University of Medical Sciences, Tehran, Iran Maryam Akhtari Rheumatology Research Center, Tehran University of Medical Sciences, Tehran, Iran AND Department of Cell and Molecular Biology, University of Tehran, Tehran, Iran Mahdi Mahmoudi Rheumatology Research Center, Tehran University of Medical Sceinces, Tehran, Iran Shayan Mostafaei Rheumatology Research Center, Tehran University of Medical Sciences, Tehran, Iran Alireza Rezaeimanesh Department of Immunology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran Massoomeh Akhlaghi Rheumatology Research Center, Tehran University of Medical Sciences, Tehran, Iran Farhad Shahram Rheumatology Research Center, Tehran University of Medical Sciences, Tehran, Iran 2017 03 07 2017 05 16 Aryl hydrocarbon receptor (AHR) is a ligand-activated transcription factor, connecting environmental stimulators with the immune system. M1 macrophages are a part of immune system that contribute to the inflammatory events in the pathogenesis of Behcet's disease (BD). The effect of AHR on the macrophages in BD patients is still unclear. In this study, we investigated the mRNA expression of AHR in the monocyte-derived and M1 macrophages in active BD patients in comparison to healthy controls. Isolated monocytes from 10 healthy controls and 10 active BD patients were differentiated to macrophages by macrophage-colony stimulating factor (M-CSF) for 7 days. Cells were then polarized to M1 macrophages by lipopolysaccharide (LPS) and interferon-γ (IFNγ) for 24h. Monocyte purity and macrophage markers expression were analyzed by flow cytometry. Analysis of AHR mRNA expression was performed by SYBR Green real-time PCR. Our results showed that AHR expression is significantly down-regulated in M1 macrophages compare to monocyte-derived macrophages. It was shown that both monocyte-derived macrophages and M1 macrophages from BD patients significantly express lower level of AHR mRNA compared to healthy individuals. Our results demonstrate an anti-inflammatory role for AHR in macrophages, which suggest that decreased AHR expression is associated with pro-inflammatory M1 macrophage and BD susceptibility. https://ijaai.tums.ac.ir/index.php/ijaai/article/view/1350 https://ijaai.tums.ac.ir/index.php/ijaai/article/download/1350/774

Tehran University of Medical Sciences Iranian Journal of Allergy, Asthma and Immunology 1735-1502 16 5 2017 10 28 425 432 EN Tahereh Khamehchian Department of Pathology, Kashan University of Medical Sciences, Kashan, Iran Eqlim Nemati Internal Medicine Department, Baqiyatallah University of Medical Sciences, Tehran, Iran Marziyeh Jazayeri Student Research Committee, Kashan University of Medical Sciences, Kashan, Iran shirin Azimi Student Research Committee, Kashan University of Medical Sciences, Kashan, Iran Hassan Nikoueinejad Nephrology and Urology Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran Hossein Akbari Trauma Research Center, Kashan University of Medical Sciences, Kashan, Iran Behnaz Irandoust Department of Pathology, Kashan University of Medical Sciences, Kashan, Iran 2017 03 04 2017 05 13 Type 1 diabetes (T1D) is the result of the autoimmune destruction of insulin-producing beta cells. Regulatory T cells (Tregs) and plasmacytoid dendritic cells (PDCs) act as mediators of peripheral tolerance. We investigated the possible alterations of such cells in peripheral blood of patients with T1D compared to normal individuals. This comparison may lead to a better understanding of the immunopathogenesis processes involved in T1D. 92 participants, including 49 patients with T1D and 43 healthy controls were studied. 3 mL of blood was taken from all participants. After isolating peripheral blood mononuclear cells (PBMCs), PDCs as well as 2 subtypes of Tregs, CD4+CD25+FoxP3+ and CD8+CD28- cells were counted by 3-colorflow cytometry. The association between such enumeration and T1D was studied by multivariate regression and discriminate function models. The frequency of CD4+CD25+FoxP3+Tregs (p=0.038) and PDCs (p=0.039) in the peripheral blood of diabetic patients was less than that in healthy subjects. Having compared some models consisting different cells as well as their combinations, we did not find any profound explanation of each subset or their combinations to identify T1D. The decrease of CD4+CD25+FoxP3+cells and PDCs in diabetic patients may suggest their role in the onset or development of the disease. Therefore, it is likely that their pharmacologic stimulation may direct immune responses towards tolerance and prevent the development or even the onset of diabetes in susceptible individuals. https://ijaai.tums.ac.ir/index.php/ijaai/article/view/1343 https://ijaai.tums.ac.ir/index.php/ijaai/article/download/1343/768

Tehran University of Medical Sciences Iranian Journal of Allergy, Asthma and Immunology 1735-1502 16 5 2017 10 28 433 442 EN Hossein Ahmadi Department of Immunology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran Ahmad Reza Jamshidi Rheumatology Research Centre, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran Mahdi Mahmoudi Rheumatology Research Centre, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran Farhad Gharibdoost Rheumatology Research Centre, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran Mahdi Vojdanian Rheumatology Research Centre, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran Mohammad Javad Fattahi Department of Immunology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran AND Institute for Cancer Research (ICR), School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran Noushin Rastkari Center for Air Pollution Research (CAPR), Institute for Environmental Research (IER), Tehran University of Medical Sciences, Tehran, Iran Zahra Aghazadeh Department of Immunology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran Abbas Mirshafiey Department of Immunology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran 2017 01 23 2017 03 12 The aim of this study was to investigate the effect of β-D-mannuronic acid (M2000) on hematological parameters in patients with active rheumatoid arthritis. This study was conducted on 25 patients with active rheumatoid arthritis (RA) (identifier: IRCT2014011213739N2). M2000 was administered orally for anemic and non-anemic RA patients at a dose of 500 mg twice daily for 12 weeks. The patients were permitted to continue the conventional treatments excluding NSAIDs. Blood samples were collected at baseline, 4 and 12 weeks after drug administration and were tested for hematological parameters. Moreover, serum levels of TNF-α and IL-6 were analysed before and after M2000 therapy compared to healthy controls using enzyme linked immunosorbent assay method. We found a significant increase in the count of red blood cells and also hemoglobin (Hb) concentration (0.9 g/dL) in anemic patients after 12 weeks of M2000 therapy (p<0.02 and p<0.01, respectively). Furthermore, our results showed an improvement in Hb level (0.45 g/dL) even in non-anemic patients who were treated by M2000 (p<0.04). The leukocytosis in RA patients, significantly decreased in both anemic and non-anemic patients after 12 weeks of M2000 therapy (p<0.02 and p<0.03, respectively). The percent of neutrophils significantly increased in anemic patients (p<0.01) while in non-anemic patients it significantly decreased after 12 weeks of M2000 therapy (p<0.01). The serum levels of IL-6 and TNF-α significantly decreased after 12 weeks of M2000 therapy (p<0.01 and p<0.04, respectively). M2000 improves hematological parameters in RA patients by its potent inhibitory effect on serum levels of TNF-α and IL-6. https://ijaai.tums.ac.ir/index.php/ijaai/article/view/1275 https://ijaai.tums.ac.ir/index.php/ijaai/article/download/1275/761

Tehran University of Medical Sciences Iranian Journal of Allergy, Asthma and Immunology 1735-1502 16 5 2017 10 28 443 451 EN Mohadese M. Farahani Department of Immunology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran Elahe Motevaseli Department of Molecular Medicine, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran Faezeh Maghsood Department of Immunology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran Maryam Heidari-Kharaji Department of Immunotherapy and Leishmania Vaccine Research, Pasteur Institute of Iran, Tehran, Iran Abbas Mirshafiey Department of Immunology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran 2016 11 16 2017 04 05 The aim of this study was to evaluate the effects of M2000, a novel non-steroidal anti-inflammatory drug (NSAID) with immunosuppressive property and without gastro-nephrotoxicitic effects on matrix metalloproteinases (MMP)-2 and (MMP)-9 in phorbol myristate acetate (PMA)-differentiated THP-1 cells. Gene expression and activity of MMP-2 and MMP-9 are inhibited respectively by the tissue inhibitor of matrix metalloproteinase (TIMP)-2 and (TIMP)-1 and are induced by extracellular matrix metalloproteinase inducer (CD147/EMMPRIN). In this study, real-time quantitative reverse transcription polymerase chain reaction (RT-PCR) was used to determine gene expression of MMP-2, MMP-9, TIMP-1, and TIMP-2. Flow cytometry and zymography were applied to determine cellular surface expression of CD147 and activity of MMP-2 and MMP-9, respectively. Our results showed that treatment of THP-1 cells with high concentration (25 µg/mL) of M2000 significantly decreased the cellular surface expression of CD147 (p<0.05) and the gene expression of MMP-2, MMP-9 and TIMP-1 (p<0.05), and inhibited the gelatinolytic activity of MMP-2 and MMP-9 (p<0.05). According to our results, M2000 can reduce inflammation through inhibition of the cellular surface expression of CD147 and decrease the gene expression and gelatinolytic activity of MMP-2 and MMP-9 in PMA-differentiated THP-1 cells. https://ijaai.tums.ac.ir/index.php/ijaai/article/view/1148 https://ijaai.tums.ac.ir/index.php/ijaai/article/download/1148/773

Tehran University of Medical Sciences Iranian Journal of Allergy, Asthma and Immunology 1735-1502 16 5 2017 10